Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a decrease of 5.9% from the September 15th total of 1,690,000 shares. Currently, 8.2% of the company’s stock are short sold. Based on an average trading volume of 285,900 shares, the short-interest ratio is currently 5.6 days.
Candel Therapeutics Stock Performance
CADL stock traded up $0.27 during midday trading on Wednesday, reaching $6.23. 352,872 shares of the company were exchanged, compared to its average volume of 1,982,879. The firm has a market capitalization of $185.23 million, a price-to-earnings ratio of -4.86 and a beta of -0.95. The business has a 50-day moving average price of $6.33 and a two-hundred day moving average price of $6.81. Candel Therapeutics has a one year low of $0.66 and a one year high of $14.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter. Equities research analysts forecast that Candel Therapeutics will post -0.91 EPS for the current year.
Insider Buying and Selling
Institutional Trading of Candel Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Candel Therapeutics during the 2nd quarter worth $31,000. Rhumbline Advisers bought a new stake in shares of Candel Therapeutics in the second quarter valued at about $143,000. Cubist Systematic Strategies LLC acquired a new position in shares of Candel Therapeutics in the second quarter valued at about $162,000. Finally, Bank of New York Mellon Corp bought a new position in Candel Therapeutics during the second quarter worth about $338,000. 13.93% of the stock is currently owned by institutional investors.
About Candel Therapeutics
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Further Reading
- Five stocks we like better than Candel Therapeutics
- What does consumer price index measure?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Why Are These Companies Considered Blue Chips?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.